Tumor-Initiating Cell Marker Identified in Myeloma
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
News
Latest News
Genetic Overlap Between Autoimmune Disease and NHL Not Supported by Genome-Wide Association Study
Researchers hypothesized that overlapping characteristics between autoimmune disease and NHL could be the result of similar genetic components.
Some Discrepancies Seen Between Real-Life and Guideline-Recommended Care of Chronic Myeloid Leukemia
An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.
Premedication With Dexamethasone May Prevent Pemetrexed-Associated Skin Rash
A retrospective study sought to determine the efficacy of dexamethasone in preventing cutaneous reactions associated with pemetrexed-based regimens for pulmonary adenocarcinoma.
New Treatment Option Approved for Patients With Myelofibrosis
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Robotic, Open Cystectomy for Bladder Cancer Offer Comparable Outcomes
In a propensity score matched analysis, robotic-assisted and open radical cystectomy for urothelial bladder cancer did not differ significantly with respect to disease recurrence and cancer-specific mortality rates.
Adding Bevacizumab to Erlotinib Fails to Improve PFS in EGFR-Mutant NSCLC
The addition of bevacizumab to erlotinib failed to improve progression-free survival in patients with EGFR-mutant non-small cell lung cancer, a phase 2 trial showed.
Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech).
Burden of Obesity-Associated Cancers Shifted to Younger Age Groups
Large study shows particular increase in the 50- to 64-year-old age group from 2000 to 2016.
Cost Burden of Disease Progression High in Multiple Myeloma
For patients receiving drug therapy, economic burden substantial across lines of therapy.
Right-Sided RCC Predicts Better Outcomes in Patients With Larger Tumors
Among patients undergoing surgery for 10 cm or larger renal cell carcinoma tumors, right-sided tumors are independently associated with improved cancer-specific survival compared with left-sided tumors, a study found.
Evidence Supporting NCCN Off-Label Recommendations Is Robust: Study
Researchers found that the off-label drug recommendations listed in the NCCN Guidelines were indeed supported by robust data.
Treatment Reduction in Intermediate-Risk Neuroblastoma Deemed Successful
For specific subsets of patients with intermediate-risk neuroblastoma, an algorithm successfully reduced treatment while maintaining survival outcomes.
Measuring Low-Density Antigen Expression in Myeloma Cells Could Identify More Candidates for CAR-T Therapy
The antigen expression level on tumors that is necessary to engage and activate CAR-T cells is not currently known.
Nurse-Led Intervention Attempts to Address Posttreatment Needs of Lymphoma Survivors
Although statistically insignificant, results of a randomized study determined the potential for nurse-led interventions as adjunct posttreatment care for lymphoma survivors.
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2019 Breast Cancer In Depth
